This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Influenza A virus subtype H3N2 haemagglutinin, recombinant
- DrugBank Accession Number
- DB16642
- Background
Not Available
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Recombinant - Synonyms
- Recombinant haemagglutinin protein-strain A (H3N2)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Supemtek Influenza A virus subtype H3N2 haemagglutinin, recombinant (45 μg) + Influenza A virus subtype H1N1 haemagglutinin, recombinant (45 μg) + Influenza B virus Victoria lineage haemagglutinin, recombinant (45 μg) + Influenza B virus Yamagata lineage haemagglutinin, recombinant (45 μg) Solution Intramuscular Sanofi Pasteur 2021-03-20 Not applicable EU 
Supemtek Influenza A virus subtype H3N2 haemagglutinin, recombinant (45 μg) + Influenza A virus subtype H1N1 haemagglutinin, recombinant (45 μg) + Influenza B virus Victoria lineage haemagglutinin, recombinant (45 μg) + Influenza B virus Yamagata lineage haemagglutinin, recombinant (45 μg) Solution Intramuscular Sanofi Pasteur 2021-03-20 Not applicable EU Supemtek Influenza A virus subtype H3N2 haemagglutinin, recombinant (45 mcg / 0.5 mL) + Influenza A virus subtype H1N1 haemagglutinin, recombinant (45 mcg / 0.5 mL) + Influenza B virus Victoria lineage haemagglutinin, recombinant (45 mcg / 0.5 mL) + Influenza B virus Yamagata lineage haemagglutinin, recombinant (45 mcg / 0.5 mL) Solution Intramuscular Sanofi Pasteur Limited 2022-10-03 Not applicable Canada 
Supemtek Influenza A virus subtype H3N2 haemagglutinin, recombinant (45 μg) + Influenza A virus subtype H1N1 haemagglutinin, recombinant (45 μg) + Influenza B virus Victoria lineage haemagglutinin, recombinant (45 μg) + Influenza B virus Yamagata lineage haemagglutinin, recombinant (45 μg) Solution Intramuscular Sanofi Pasteur 2021-03-20 Not applicable EU Supemtek Influenza A virus subtype H3N2 haemagglutinin, recombinant (45 μg) + Influenza A virus subtype H1N1 haemagglutinin, recombinant (45 μg) + Influenza B virus Victoria lineage haemagglutinin, recombinant (45 μg) + Influenza B virus Yamagata lineage haemagglutinin, recombinant (45 μg) Solution Intramuscular Sanofi Pasteur 2021-03-20 Not applicable EU Supemtek Influenza A virus subtype H3N2 haemagglutinin, recombinant (45 μg) + Influenza A virus subtype H1N1 haemagglutinin, recombinant (45 μg) + Influenza B virus Victoria lineage haemagglutinin, recombinant (45 μg) + Influenza B virus Yamagata lineage haemagglutinin, recombinant (45 μg) Solution Intramuscular Sanofi Pasteur 2021-03-20 Not applicable EU Supemtek Influenza A virus subtype H3N2 haemagglutinin, recombinant (45 μg) + Influenza A virus subtype H1N1 haemagglutinin, recombinant (45 μg) + Influenza B virus Victoria lineage haemagglutinin, recombinant (45 μg) + Influenza B virus Yamagata lineage haemagglutinin, recombinant (45 μg) Solution Intramuscular Sanofi Pasteur 2021-03-20 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Prevention Influenza immunization 2 3 Recruiting Prevention Obesity, Morbid / Obesity, Severe 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at March 20, 2021 17:47 / Updated at March 21, 2021 02:08